TESSA THERAPEUTICS
Tessa Therapeutics is a provider of therapy designed to focus on T cell therapy for solid tumors. The company's therapy specializes in developing virus specific T-cells and CAR T cells for the treatment of lymphoma, enabling healthcare providers to treat cancer patients and improve their lives.
TESSA THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2001-01-01
Address:
Singapore, Central Region, Singapore
Country:
Singapore
Website Url:
http://www.tessacell.com
Total Employee:
101+
Status:
Active
Contact:
(656)384-0755
Email Addresses:
[email protected]
Total Funding:
256 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail Person Schema Google Google Cloud Gravatar Profiles Ubuntu Microsoft
Similar Organizations
Amyloid Solution
Amyloid Solution is a developer of therapy intended to overcome Alzheimer by developing modifying treatments.
Atara Biotherapeutics
Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.
JW Therapeutics
JW Therapeutics is a developer of cell-based therapy technologies created to revolutionize cancer treatment.
OBiO Technology
OBiO Technology is providing overall solution of viral based gene therapy CRO services, and CDMO/CMO services.
ONK Therapeutics
ONK Therapeutics is an innovative cell therapy organisation.
Pluri
Pluri is at the forefront of a biotech revolution that promotes global well-being and sustainability.
Shanghai Cell Therapy Group
Shanghai Cell Therapy Group is a provider of cellular diagnosis center combining cellular research and treatment services.
Sino Biological
Sino Biological is a specialist provider of protein, antibody and gene products.
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-03-23 | Euchloe Bio | Euchloe Bio acquired by Tessa Therapeutics | N/A |
Investors List
Heritas Capital
Heritas Capital investment in Series A - Tessa Therapeutics
EDBI
EDBI investment in Series A - Tessa Therapeutics
Temasek Holdings
Temasek Holdings investment in Series A - Tessa Therapeutics
Polaris Partners
Polaris Partners investment in Series A - Tessa Therapeutics
Heliconia Capital Management
Heliconia Capital Management investment in Series A - Tessa Therapeutics
Far East Ventures
Far East Ventures investment in Series E - Tessa Therapeutics
Temasek Holdings
Temasek Holdings investment in Private Equity Round - Tessa Therapeutics
Heliconia Capital Management
Heliconia Capital Management investment in Private Equity Round - Tessa Therapeutics
EDBI
EDBI investment in Private Equity Round - Tessa Therapeutics
Karst Peak Capital
Karst Peak Capital investment in Private Equity Round - Tessa Therapeutics
Newest Events participated
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-22 | Tessa Therapeutics Appoints Thomas Willemsen as President and CEO |
| 2022-04-04 | Tessa Therapeutics Appoints Wilson W. Cheung as Chief Financial Officer |
Official Site Inspections
http://www.tessacell.com Semrush global rank: 6.03 M Semrush visits lastest month: 1.35 K
- Host name: a67c48129651a0940.awsglobalaccelerator.com
- IP address: 76.223.67.189
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Tessa Therapeutics"
Tessa Therapeutics - Overview, News & Similar companies
May 11, 2023 A high-level source in Marketing has indicated that the organization is currently sourcing professional services for it delivery & it strategy. See all scoops ... +65 63840755 …See details»
Tessa Therapeutics - Crunchbase Company Profile
Tessa Therapeutics is a provider of therapy designed to focus on T cell therapy for solid tumors. The company's therapy specializes in developing virus specific T-cells and CAR T cells for the treatment of lymphoma, enabling healthcare …See details»
Tessa Therapeutics’ ‘Off-the-Shelf’ CAR-T Therapy Shows …
Jun 16, 2023 Tessa Therapeutics Ltd. 78% Overall Response Rate (14/18 patients), including seven patients exhibiting a complete response to TT11X allogeneic CAR-T therapySee details»
Tessa Therapeutics Provides Strategic Outlook and Corporate
Jan 3, 2023 For more information on Tessa, visit www.tessacell.com. Cautionary Note on Forward Looking Statements This press release contains forward-looking statements (within …See details»
Tessa Therapeutics Appoints Wilson W. Cheung as Chief Financial …
Apr 4, 2022 25+ year industry executive to oversee Tessa’s financial management, investor relations, and business development strategySINGAPORE, April 04, 2022 (GLOBE …See details»
Tessa Therapeutics Provides Strategic Outlook and Corporate …
Jan 3, 2023 Tessa to prioritize allogeneic CAR-T cell therapy platform following strong safety and efficacy data presented during ASH 2022SINGAPORE, Jan. 03, 2023 (GLOBE …See details»
Tessa Therapeutics Announces Presentation of Autologous and
Nov 3, 2021 For more information on Tessa, visit www.tessacell.com. Cautionary Note on Forward Looking Statements This press release contains forward-looking statements (within …See details»
Tessa Therapeutics’ ‘Off-the-Shelf’ CAR-T Therapy Shows
Jun 16, 2023 78% Overall Response Rate (14/18 patients), including seven patients exhibiting a complete response to TT11X allogeneic CAR-T therapy; Safety data encouraging with no graft …See details»
Tessa Therapeutics’ Autologous and Allogeneic Cell Therapy
SINGAPORE, May 30, 2023 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological …See details»
Tessa Therapeutics Announces Positive, Topline Data from …
May 14, 2021 For more information on Tessa, please visit www.tessacell.com. Cautionary Note on Forward Looking Statements This press release contains forward-looking statements …See details»
Tessa Therapeutics Announces Successful Dosing of First Patient …
Feb 10, 2021 BEDMINSTER, N.J. and SINGAPORE, Feb. 10, 2021 /PRNewswire/ -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation …See details»
Tessa Therapeutics Receives PRIME Designation from European …
Jan 18, 2021 BEDMINSTER, N.J. and SINGAPORE, Jan. 18, 2021 /PRNewswire/ -- Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation …See details»
Tessa Therapeutics Provides Strategic Outlook and Corporate
Jan 3, 2023 For more information on Tessa, visit www.tessacell.com. Cautionary Note on Forward Looking Statements This press release contains forward-looking statements (within …See details»
Tessa Therapeutics Showcases Positive Clinical Data from
Dec 11, 2021 For more information on Tessa, visit www.tessacell.com. Cautionary Note on Forward Looking Statements This press release contains forward-looking statements (within …See details»
Tessa Therapeutics Announces Updated Safety, Efficacy and …
Dec 12, 2022 Updated Results from CHARIOT Phase 2 trial presented at the 2022 ASH Annual Meeting indicate a 73.3% overall response rate and 60% complete response rate from 15 …See details»
Tessa Therapeutics Completes US$126 Million Financing Led
Jun 9, 2022 [email protected]. Tessa Therapeutics Media Contact. Tiberend Strategic Advisors, Inc. Bill Borden +1-732-910-1620 [email protected]. Dave Schemelia +1-609 …See details»
Tessa Therapeutics’ Autologous and Allogeneic Cell Therapy Data …
May 30, 2023 New data from clinical trials of TT11 and TT11X to be featured in oral and poster presentationsSINGAPORE, May 30, 2023 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. …See details»
Tessa Therapeutics Announces New Clinical Data from Phase 1
Dec 10, 2022 For more information on Tessa, visit www.tessacell.com. Cautionary Note on Forward Looking Statements This press release contains forward-looking statements (within …See details»
Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf ...
Sep 14, 2022 Tessa developing allogeneic “off-the-shelf” CD30-CAR EBVST cell therapy – TT11X – targeting relapsed or refractory CD30-positive lymphomasSINGAPORE, Sept. 14, …See details»